# Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

> **NCT01121562** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01121562
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-07
- **Final completion:** 2013-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121562, "Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01121562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*